BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 24302750)

  • 1. Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma.
    Else T; Williams AR; Sabolch A; Jolly S; Miller BS; Hammer GD
    J Clin Endocrinol Metab; 2014 Feb; 99(2):455-61. PubMed ID: 24302750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study.
    Weigand I; Altieri B; Lacombe AMF; Basile V; Kircher S; Landwehr LS; Schreiner J; Zerbini MCN; Ronchi CL; Megerle F; Berruti A; Canu L; Volante M; Paiva I; Della Casa S; Sbiera S; Fassnacht M; Fragoso MCBV; Terzolo M; Kroiss M
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32449514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma.
    Berruti A; Grisanti S; Pulzer A; Claps M; Daffara F; Loli P; Mannelli M; Boscaro M; Arvat E; Tiberio G; Hahner S; Zaggia B; Porpiglia F; Volante M; Fassnacht M; Terzolo M
    J Clin Endocrinol Metab; 2017 Apr; 102(4):1358-1365. PubMed ID: 28324035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group.
    Postlewait LM; Ethun CG; Tran TB; Prescott JD; Pawlik TM; Wang TS; Glenn J; Hatzaras I; Shenoy R; Phay JE; Keplinger K; Fields RC; Jin LX; Weber SM; Salem A; Sicklick JK; Gad S; Yopp AC; Mansour JC; Duh QY; Seiser N; Solorzano CC; Kiernan CM; Votanopoulos KI; Levine EA; Staley CA; Poultsides GA; Maithel SK
    J Am Coll Surg; 2016 Apr; 222(4):480-90. PubMed ID: 26775162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group.
    Icard P; Goudet P; Charpenay C; Andreassian B; Carnaille B; Chapuis Y; Cougard P; Henry JF; Proye C
    World J Surg; 2001 Jul; 25(7):891-7. PubMed ID: 11572030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers.
    Fassnacht M; Johanssen S; Fenske W; Weismann D; Agha A; Beuschlein F; Führer D; Jurowich C; Quinkler M; Petersenn S; Spahn M; Hahner S; Allolio B;
    J Clin Endocrinol Metab; 2010 Nov; 95(11):4925-32. PubMed ID: 20668036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical study and treatment results of adrenocortical carcinoma patients presented in Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore.
    Khan MS; Ali A; Tariq I; Khan MA; Bakar MA; Anwar AW
    J Pak Med Assoc; 2019 May; 69(5):717-719. PubMed ID: 31105294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
    Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
    Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis, treatment and outcome of adrenocortical cancer.
    Mihai R
    Br J Surg; 2015 Mar; 102(4):291-306. PubMed ID: 25689291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma.
    Fassnacht M; Hahner S; Polat B; Koschker AC; Kenn W; Flentje M; Allolio B
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4501-4. PubMed ID: 16895957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant mitotane treatment for adrenocortical carcinoma.
    Terzolo M; Angeli A; Fassnacht M; Daffara F; Tauchmanova L; Conton PA; Rossetto R; Buci L; Sperone P; Grossrubatscher E; Reimondo G; Bollito E; Papotti M; Saeger W; Hahner S; Koschker AC; Arvat E; Ambrosi B; Loli P; Lombardi G; Mannelli M; Bruzzi P; Mantero F; Allolio B; Dogliotti L; Berruti A
    N Engl J Med; 2007 Jun; 356(23):2372-80. PubMed ID: 17554118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contemporary management of adrenocortical carcinoma.
    Zini L; Porpiglia F; Fassnacht M
    Eur Urol; 2011 Nov; 60(5):1055-65. PubMed ID: 21831516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Adrenocortical Carcinoma.
    Vaidya A; Nehs M; Kilbridge K
    Surg Pathol Clin; 2019 Dec; 12(4):997-1006. PubMed ID: 31672303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adrenocortical carcinoma.
    Baudin E;
    Endocrinol Metab Clin North Am; 2015 Jun; 44(2):411-34. PubMed ID: 26038209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National Treatment Practice for Adrenocortical Carcinoma: Have They Changed and Have We Made Any Progress?
    Tierney JF; Chivukula SV; Poirier J; Pappas SG; Schadde E; Hertl M; Kebebew E; Keutgen X
    J Clin Endocrinol Metab; 2019 Dec; 104(12):5948-5956. PubMed ID: 31361313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence.
    Calabrese A; Basile V; Puglisi S; Perotti P; Pia A; Saba L; Berchialla P; Porpiglia F; Veltri A; Volante M; Reimondo G; Berruti A; Terzolo M
    Eur J Endocrinol; 2019 Jun; 180(6):387-396. PubMed ID: 30991359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry.
    Michalkiewicz E; Sandrini R; Figueiredo B; Miranda EC; Caran E; Oliveira-Filho AG; Marques R; Pianovski MA; Lacerda L; Cristofani LM; Jenkins J; Rodriguez-Galindo C; Ribeiro RC
    J Clin Oncol; 2004 Mar; 22(5):838-45. PubMed ID: 14990639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane.
    Grubbs EG; Callender GG; Xing Y; Perrier ND; Evans DB; Phan AT; Lee JE
    Ann Surg Oncol; 2010 Jan; 17(1):263-70. PubMed ID: 19851811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How is adrenocortical cancer being managed in the UK?
    Aspinall SR; Imisairi AH; Bliss RD; Scott-Coombes D; Harrison BJ; Lennard TW
    Ann R Coll Surg Engl; 2009 Sep; 91(6):489-93. PubMed ID: 19558758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adrenocortical carcinoma: clinicopathological features, prognostic factors and outcome.
    Keskin S; Taş F; Vatansever S
    Urol Int; 2013; 90(4):435-8. PubMed ID: 23343838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.